Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| GlobalFoundries | Alibaba Group | Pfizer | |
|---|---|---|---|
| Moat rating | narrow The FY2025 20-F gives a measured lock-in: approximately 63% of 2025 wafer shipment volume was single-sourced business - products GF says "can only be manufactured with our technology or cannot be manufactured elsewhere without significant customer redesigns" - and long-term agreements carried an aggregate remaining revenue commitment of approximately $11 billion at 31 December 2025, as "binding, multi-year, reciprocal minimum purchase and supply commitments". That advantage is bounded by admissions in the same filing: "some of our competitors may offer more advanced or differentiated technologies than we do and some have greater access to capital and substantially greater production capacity, research and development... including access to government subsidies"; China's mature-node "foundry capacity is expected to grow faster than expected demand at those nodes"; and GF "renegotiated a number of LTAs with certain of our customers, including in 2025, as a result of which some of our LTAs now have longer commitment periods... and some of our LTAs have lower pricing or volume commitments than originally negotiated". Gross margin of 24.9% in 2025 ($1,690m on $6,791m of net revenue) on essentially flat revenue is the economics of a position that is defended rather than uncontested. | wide The FY2026 20-F rests on two entrenched positions: a commerce ecosystem the filing ties to 'the world's largest online retail market' with 'over 1.1 billion Internet users,' and a cloud business whose 'Cloud Intelligence Group's external revenue growth accelerated to 40% in the final quarter of fiscal 2026, with AI-related products accounting for 30% of this revenue.' Two durable franchises under one roof is a wide moat — bounded by China regulation and US ICTS cloud controls the same filing flags. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. |
| Moat type | switching costs The filing rules out scale as the source: GF concedes competitors with "substantially greater production capacity, research and development" and its four fabs held roughly 2.8 million wafers per annum of installed capacity at end-2025 against a $6.8bn revenue base. The mechanism it names instead is the cost of moving a qualified design - "[g]iven the time and costs associated with moving a single-sourced product to a competitor, clients are more likely to continue awarding us single-source contracts for such products" - and it is quantified at approximately 63% of 2025 wafer shipment volume. It is contractually reinforced by the ~$11bn of remaining LTA revenue commitment, which GF says continues to matter "for certain longer term, more durable end markets, such as automotive", where 21% of 2025 net revenue ($1,410m) now sits. | network effects The 20-F names 'the network effects of our ecosystems' among the factors its business depends on: Taobao and Tmall, Alipay, Amap and the rest compound as buyers, sellers and services reinforce each other across one integrated ecosystem. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. |
| Leadership | fast follower The 20-F places GF inside a group of "five major foundries (including four scaled pure-play foundries) that accounted for the vast majority of worldwide foundry revenue in 2025", naming TSMC first among key competitors along with UMC and SMIC, and separately conceding competitors with "more advanced or differentiated technologies than we do" and "substantially greater production capacity, research and development, marketing and other resources". GF does not compete for the leading edge at all; its stated pillars are differentiated RF, FDX, silicon photonics, power and feature-rich CMOS plus geographic diversity. That is an established, scaled participant operating inside a pace set elsewhere, not one setting it, and not one shut out of the top tier. | clear leader The 20-F claims leadership in applied AI ('strengthened our leadership in applied AI') and roots the commerce business in the world's largest online retail market; Alibaba Cloud is the leading China hyperscaler pivoting to AI, per the segment discussion — a category leader in both its home markets. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' |
| Pricing power | moderate Gross margin was 24.9% in 2025 ($1,690m on $6,791m) versus 24.5% in 2024 ($1,651m on $6,750m) - held, not expanded, even though average shipment utilization across the global fabs rose from 77% to 86%, so most of the volume gain was absorbed rather than dropping through. The filing states outright that "the market prices for technology and services tend to fall over time, except in times of extreme supply shortage", and discloses LTAs renegotiated in 2025 to "lower pricing or volume commitments than originally negotiated". Against that, GF says wafer price "varies significantly across technology platforms" and that devices with "richer feature sets, higher performance, better yields and greater system-level integration... generally command higher wafer prices". Price-setting inside designed-in single-sourced sockets, price-taking at the competitive margin. | moderate Ecosystem lock-in and cloud scale support pricing, but the filing warns that if 'user activity and engagement in our ecosystem may decrease … our market share and profitability may be negatively affected,' and Chinese e-commerce/cloud competition is intense — real but capped pricing power. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. |
| Summary | GlobalFoundries is a pure-play specialty foundry that deliberately does not contest the leading edge. Its FY2025 20-F frames the business around six differentiated technology lines - feature-rich CMOS, ultra-low-power CMOS (FinFET and FDX), silicon photonics, RF, power, and, new in 2025, processor IP via the MIPS acquisition - manufactured at four fabs in Malta NY, Burlington VT, Dresden and Singapore, which GF describes as making it "the only scaled foundry with a global manufacturing footprint spanning the United States, Europe, and Asia operating for more than a decade". The defence that shows up in the numbers is design lock-in rather than cost: approximately 63% of 2025 wafer shipment volume was single-sourced, and ~$11bn of long-term agreement revenue commitment remained at year-end. What limits it is visible in the same document - competitors with more capital, more capacity and, in some cases, more advanced technology; mature-node capacity in China expected to outgrow demand at 28nm and larger; TSMC, Samsung, Intel, Texas Instruments and UMC all building in the United States, Europe or Singapore, which erodes the geographic-diversity argument GF calls "one of our key advantages". Pricing reflects that balance: 2025 gross margin of 24.9% against 24.5% in 2024 even as shipment utilization rose from 77% to 86%, with some LTAs renegotiated to lower pricing. AI exposure is real but indirect - Communications, Infrastructure & Data Center was 11% of 2025 net revenue, and GF's AI content is optical interconnect, RF, sensing, power and edge processor IP rather than accelerator logic. | Alibaba is a commerce network and an AI cloud fused into one ecosystem. The retail side draws its moat from network effects the filing names explicitly, rooted in the world's largest online retail market; the cloud side is pivoting hard into AI — Alibaba Cloud's 'growth engine fully pivots from traditional compute and storage to models, AI compute, and agent services,' anchored by the in-house Qwen family (Qwen3.7-Max 'specifically engineered for agents') and the PAI platform. The 20-F's own framing is 'leading full-stack capabilities across the AI value chain.' The counterweights are structural rather than competitive: a Cayman VIE structure, China's regulatory environment, and the US Commerce Department's proposed ICTS cloud-computing controls the filing discloses. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. |
| Chain position | Pure-play specialty foundry. Inputs are silicon and specialised SOI wafers bought under multiple long-term agreements with principal suppliers, "the largest of which is Soitec", plus externally sourced EDA tools and third-party IP. Output is finished semiconductor wafers, approximately 89% of 2025 net revenue, sold to fabless designers and IDMs and delivered through the GlobalSolutions ecosystem of IP providers, EDA vendors, OSAT partners and design-service firms; the remaining ~11% is photomasks, sourcing and post-fab services, and IP licence and royalty income. Manufacturing sits at four sites - Malta NY, Burlington VT, Dresden and Singapore - with roughly 239,000 square metres of clean room and about 2.8 million wafers per annum installed capacity at end-2025. Position in the AI chain is one step removed from accelerators: Communications, Infrastructure & Data Center was 11% of 2025 net revenue ($745m), with content in optical interconnect, RF front-ends, timing and power, alongside edge-AI processor IP from the MIPS acquisition. | Layer-8 hyperscaler + AI-application incumbent: Alibaba Cloud supplies AI compute and the Qwen models while the commerce ecosystem is a vast applied-AI distribution surface. | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.06 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.38 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. |